Sign up to save your podcasts
Or
Share Special Episode: Thomas G Schmidt - 21st BIO
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Special Episode: Thomas G Schmidt - 21st BIO
Powered by Protein Production Technology International
Why do so many promising biotechnology breakthroughs fail to reach commercial scale?
In this episode of the Protein Production Technology International podcast, Nick Bradley sat down with Thomas G. Schmidt, CEO of 21st.BIO, to discuss one of the industry's biggest challenges: bridging the 'Valley of Death' between laboratory success and industrial-scale production.
Drawing on the company's roots within the Novo Group ecosystem, Schmidt explained how 21st.BIO is helping startups accelerate commercialization by providing access to proven technology platforms, industrial expertise, and large-scale production capabilities. The conversation explored why scientific innovation alone is rarely enough and why companies must demonstrate credible pathways to manufacturing at scale.
Schmidt also shared his perspective on the future economics of precision fermentation, including why achieving competitive production costs, improving titers, and maximizing carbon conversion efficiency will be critical to long-term success. The discussion examined 21st.BIO's work with beta-lactoglobulin (BLG), the importance of moving beyond sustainability-focused narratives, and the need to build businesses that can compete on performance and economics.
The episode also looked at how biotechnology can evolve from replicating existing proteins to creating entirely new nutritional possibilities, unlocking greater efficiency and helping meet growing global demand for protein.
From scale-up and manufacturing to investment, partnerships, and the future of precision fermentation, this conversation offered valuable insights into what it will take to transform breakthrough science into commercially viable food production.
A must-listen for fermentation companies, investors, food manufacturers, technology developers, and anyone interested in the realities of scaling the next generation of protein production.
View all episodes
By FPG MediaPowered by Protein Production Technology International
Why do so many promising biotechnology breakthroughs fail to reach commercial scale?
In this episode of the Protein Production Technology International podcast, Nick Bradley sat down with Thomas G. Schmidt, CEO of 21st.BIO, to discuss one of the industry's biggest challenges: bridging the 'Valley of Death' between laboratory success and industrial-scale production.
Drawing on the company's roots within the Novo Group ecosystem, Schmidt explained how 21st.BIO is helping startups accelerate commercialization by providing access to proven technology platforms, industrial expertise, and large-scale production capabilities. The conversation explored why scientific innovation alone is rarely enough and why companies must demonstrate credible pathways to manufacturing at scale.
Schmidt also shared his perspective on the future economics of precision fermentation, including why achieving competitive production costs, improving titers, and maximizing carbon conversion efficiency will be critical to long-term success. The discussion examined 21st.BIO's work with beta-lactoglobulin (BLG), the importance of moving beyond sustainability-focused narratives, and the need to build businesses that can compete on performance and economics.
The episode also looked at how biotechnology can evolve from replicating existing proteins to creating entirely new nutritional possibilities, unlocking greater efficiency and helping meet growing global demand for protein.
From scale-up and manufacturing to investment, partnerships, and the future of precision fermentation, this conversation offered valuable insights into what it will take to transform breakthrough science into commercially viable food production.
A must-listen for fermentation companies, investors, food manufacturers, technology developers, and anyone interested in the realities of scaling the next generation of protein production.